Navigation Links
Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
Date:2/28/2013

(PRWEB) February 28, 2013

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. The massive $45b poured in acquiring innovation by Japanese companies does not justify its value as the key catalysts from Japan are in-house candidates.

Changing political scenario in Japan will accelerate the pace of reforms in Japan as recently; the Liberal Democratic Party (LDP) of Japan came back into power replacing the short tenure of the Democratic Party of Japan (DPJ). LDP was the pioneer initiator of major healthcare reforms with a focus on curbing healthcare costs by means of enhancing generic drugs penetration. This report discusses in details about the implications of these changes on Innovator and generic domestic Japanese pharma companies.

Global companies on the other hand are going to see a favorable scenario in coming years - expected launches in 2013-2014 from global companies will increase competition to domestic players mainly in the respiratory, oncology and rheumatoid arthritis therapy areas, and will increase overall market size of Diabetes and Osteoporosis markets.

Going forward, generic companies will continue to witness a growth story.

Leading players featured in this report include Daiichi Sankyo, Kyorin, Mitsubishi Tanabe, Shionogi, Eisai, Astellas, Chugai, Dainippon Sumitomo, Kyowa Hakko Kirin, Nippon Chemiphar, Sawai, Takeda, and Towa.

For more information please visit http://www.researchandmarkets.com/research/dz9d22/global

Research and Markets
Laura Wood, Senior Manager.
press(at)researchandmarkets(dot)com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Biotechnology

Read the full story at http://www.prweb.com/releases/2013/2/prweb10476447.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. OrbusNeichs Combo Dual Therapy Stentā„¢ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
2. Spectrometry Market (Atomic, Molecular and Mass Spectrometry) - Global Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017
3. CoreLab Partners Opens Office in Tokyo, Japan
4. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
5. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
6. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
7. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. First Baby With Artificial Heart in Japan
10. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
11. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch ... performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU technical ...
(Date:2/10/2016)... ... 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the ... it has been selected to present at the Cavendish Global Health Impact Forum taking ... The purpose of the Forum is to help family offices and foundations develop and ...
(Date:2/9/2016)... ... ... Date and time: March 1, 2016, 5:30 p.m. to ... of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The Baruch ... house for participants to learn about a new Master of Biomedical Science (MBS) ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
Breaking Biology News(10 mins):